#ES­MO20: As­traZeneca aims to spur PRO­found shift in prostate can­cer treat­ment with Lyn­parza OS da­ta

As­traZeneca has un­veiled the fi­nal, ma­ture over­all sur­vival da­ta that ce­ment­ed Lyn­parza’s first ap­proval in prostate can­cer ap­proval — tout­ing its lead against ri­vals with the on­ly PARP in­hibitor to have demon­strat­ed such ben­e­fit.

But get­ting the Mer­ck-part­nered drug to the right pa­tients re­mains a chal­lenge, some­thing the com­pa­nies are hop­ing to change with the new da­ta cut.

The OS num­bers on the sub­group with BR­CA1/2 or ATM-mu­tat­ed metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer are sim­i­lar to the first look on of­fer when the FDA ex­pand­ed the la­bel in May: Lyn­parza re­duced the risk of death by 31% ver­sus Xtan­di and Zyti­ga. Pa­tients on Lyn­parza lived a me­di­an of 19.1 months, com­pared to 14.7 months for the an­ti-an­dro­gen ther­a­pies (p = 0.0175).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER